JP2017523207A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523207A5 JP2017523207A5 JP2017505609A JP2017505609A JP2017523207A5 JP 2017523207 A5 JP2017523207 A5 JP 2017523207A5 JP 2017505609 A JP2017505609 A JP 2017505609A JP 2017505609 A JP2017505609 A JP 2017505609A JP 2017523207 A5 JP2017523207 A5 JP 2017523207A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- cell
- lymphoma
- cell lymphoma
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002246 antineoplastic agent Substances 0.000 claims 12
- 210000003719 b-lymphocyte Anatomy 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 7
- 230000036210 malignancy Effects 0.000 claims 7
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 6
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 5
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 claims 5
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims 5
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 claims 5
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims 5
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 claims 5
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 5
- 101150113681 MALT1 gene Proteins 0.000 claims 5
- 102000057613 Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Human genes 0.000 claims 5
- 108700026676 Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Proteins 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 229960001507 ibrutinib Drugs 0.000 claims 5
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 5
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 3
- -1 Subtox Chemical compound 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- MCUJKPPARUPFJM-UWCCDQBKSA-N (5z)-5-[[2-[(3r)-3-aminopiperidin-1-yl]-3-phenylphenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1[C@H](N)CCCN1C(C(=CC=C1)C=2C=CC=CC=2)=C1\C=C/1C(=O)NC(=O)S\1 MCUJKPPARUPFJM-UWCCDQBKSA-N 0.000 claims 2
- MQGPSCMMNJKMHQ-UHFFFAOYSA-N 7-hydroxyflavone Chemical compound C=1C(O)=CC=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 MQGPSCMMNJKMHQ-UHFFFAOYSA-N 0.000 claims 2
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 230000001093 anti-cancer Effects 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 claims 2
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- CVCLJVVBHYOXDC-IAZSKANUSA-N (2z)-2-[(5z)-5-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole Chemical compound COC1=C\C(=C/2N=C3C=CC=CC3=C\2)N\C1=C/C=1NC(C)=CC=1C CVCLJVVBHYOXDC-IAZSKANUSA-N 0.000 claims 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- AATMNHPDEZNXEK-UHFFFAOYSA-N 2-(n-[2-(4-cyanoanilino)acetyl]-3-fluoroanilino)-n-cyclohexyl-2-(2-methylphenyl)acetamide Chemical compound CC1=CC=CC=C1C(C(=O)NC1CCCCC1)N(C=1C=C(F)C=CC=1)C(=O)CNC1=CC=C(C#N)C=C1 AATMNHPDEZNXEK-UHFFFAOYSA-N 0.000 claims 1
- GZLNOSRHZLTDMT-UHFFFAOYSA-N 2-(n-[2-(benzimidazol-1-yl)acetyl]-3-fluoroanilino)-n-cyclopentyl-2-(2-methylphenyl)acetamide Chemical compound CC1=CC=CC=C1C(C(=O)NC1CCCC1)N(C=1C=C(F)C=CC=1)C(=O)CN1C2=CC=CC=C2N=C1 GZLNOSRHZLTDMT-UHFFFAOYSA-N 0.000 claims 1
- AQVFETGXIRKVAQ-UHFFFAOYSA-N 4-[3-(4-chlorophenyl)-2,1-benzisoxazol-5-yl]pyrimidin-2-amine Chemical compound NC1=NC=CC(C2=CC3=C(C=4C=CC(Cl)=CC=4)ON=C3C=C2)=N1 AQVFETGXIRKVAQ-UHFFFAOYSA-N 0.000 claims 1
- SRQYLNYQAPCPIR-UHFFFAOYSA-N 4-[4-(5,5-dimethyl-4H-thiazol-2-yl)-1-piperazinyl]-6-propylthieno[2,3-d]pyrimidine Chemical compound N1=CN=C2SC(CCC)=CC2=C1N(CC1)CCN1C1=NCC(C)(C)S1 SRQYLNYQAPCPIR-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 claims 1
- 108010079505 Endostatins Proteins 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 101150054675 MIM1 gene Proteins 0.000 claims 1
- MHXGEROHKGDZGO-UHFFFAOYSA-N N-[(1-methyl-4-piperidinyl)methyl]-3-[3-(trifluoromethoxy)phenyl]-6-imidazo[1,2-b]pyridazinamine Chemical compound C1CN(C)CCC1CNC1=NN2C(C=3C=C(OC(F)(F)F)C=CC=3)=CN=C2C=C1 MHXGEROHKGDZGO-UHFFFAOYSA-N 0.000 claims 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 1
- ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 claims 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 claims 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical group OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- 229960004630 chlorambucil Drugs 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- 229930000755 gossypol Natural products 0.000 claims 1
- 229950005277 gossypol Drugs 0.000 claims 1
- 208000021173 high grade B-cell lymphoma Diseases 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 1
- WIJZXSAJMHAVGX-DHLKQENFSA-N ivosidenib Chemical compound FC1=CN=CC(N([C@H](C(=O)NC2CC(F)(F)C2)C=2C(=CC=CC=2)Cl)C(=O)[C@H]2N(C(=O)CC2)C=2N=CC=C(C=2)C#N)=C1 WIJZXSAJMHAVGX-DHLKQENFSA-N 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 claims 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims 1
- 229960004963 mesalazine Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical group O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- VRQXRVAKPDCRCI-ZNMIVQPWSA-N n-[4-[(1r,3s,5s)-3-amino-5-methylcyclohexyl]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide Chemical compound C1[C@H](C)C[C@H](N)C[C@@H]1C1=CC=NC=C1NC(=O)C1=CC=C(F)C(C=2C(=CC=CC=2F)F)=N1 VRQXRVAKPDCRCI-ZNMIVQPWSA-N 0.000 claims 1
- FNYGWXSATBUBER-UHFFFAOYSA-N n-cyclohexyl-2-(3-fluoro-n-[2-(2-methylimidazol-1-yl)acetyl]anilino)-2-(2-methylphenyl)acetamide Chemical compound CC1=NC=CN1CC(=O)N(C=1C=C(F)C=CC=1)C(C=1C(=CC=CC=1)C)C(=O)NC1CCCCC1 FNYGWXSATBUBER-UHFFFAOYSA-N 0.000 claims 1
- 229950006584 obatoclax Drugs 0.000 claims 1
- 229960002450 ofatumumab Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- CBHCDHNUZWWAPP-UHFFFAOYSA-N pecazine Chemical compound C1N(C)CCCC1CN1C2=CC=CC=C2SC2=CC=CC=C21 CBHCDHNUZWWAPP-UHFFFAOYSA-N 0.000 claims 1
- 229950007538 pecazine Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000004180 plasmocyte Anatomy 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 229960003598 promazine Drugs 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- 230000003393 splenic effect Effects 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960002784 thioridazine Drugs 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462034997P | 2014-08-08 | 2014-08-08 | |
| US62/034,997 | 2014-08-08 | ||
| US201462082972P | 2014-11-21 | 2014-11-21 | |
| US62/082,972 | 2014-11-21 | ||
| US201462086162P | 2014-12-01 | 2014-12-01 | |
| US62/086,162 | 2014-12-01 | ||
| US201562196251P | 2015-07-23 | 2015-07-23 | |
| US62/196,251 | 2015-07-23 | ||
| PCT/US2015/044095 WO2016022853A1 (en) | 2014-08-08 | 2015-08-06 | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017523207A JP2017523207A (ja) | 2017-08-17 |
| JP2017523207A5 true JP2017523207A5 (enExample) | 2018-09-13 |
Family
ID=55264587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017505609A Pending JP2017523207A (ja) | 2014-08-08 | 2015-08-06 | ブルトン型チロシンキナーゼ阻害薬の組み合わせ及びそれらの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9730938B2 (enExample) |
| EP (1) | EP3177366A4 (enExample) |
| JP (1) | JP2017523207A (enExample) |
| CN (1) | CN106714909A (enExample) |
| AU (1) | AU2015300966A1 (enExample) |
| BR (1) | BR112017002232A2 (enExample) |
| CA (1) | CA2956550A1 (enExample) |
| MX (1) | MX2017001656A (enExample) |
| TW (1) | TWI586354B (enExample) |
| WO (1) | WO2016022853A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX342405B (es) | 2010-06-03 | 2016-09-28 | Pharmacyclics Inc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
| SMT202100674T1 (it) | 2014-08-11 | 2022-01-10 | Acerta Pharma Bv | Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2 |
| WO2016071770A2 (en) * | 2014-11-05 | 2016-05-12 | Janssen Pharmaceutica Nv | Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same |
| EA201892284A1 (ru) | 2016-05-27 | 2019-08-30 | Тг Терапьютикс, Инк. | Комбинация антитела против cd20, селективного ингибитора pi3-киназы-дельта и ингибитора btk для лечения b-клеточных пролиферативных расстройств |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| JP2020516654A (ja) | 2017-04-13 | 2020-06-11 | センティ バイオサイエンシズ インコーポレイテッド | 組み合わせがん免疫療法 |
| PE20200336A1 (es) | 2017-07-14 | 2020-02-14 | Janssen Pharmaceutica Nv | Formulaciones a largo plazo |
| WO2019070777A2 (en) * | 2017-10-04 | 2019-04-11 | University Of Maryland, Baltimore County | PIM KINASE INHIBITORS IN COMBINATION WITH AUTOPHAGIA INHIBITORS FOR THE TREATMENT OF CANCERS |
| TW202014184A (zh) * | 2018-04-30 | 2020-04-16 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合 |
| WO2019213184A1 (en) | 2018-05-03 | 2019-11-07 | Juno Therapeutics, Inc. | Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor |
| CN111053777A (zh) * | 2018-10-16 | 2020-04-24 | 正大天晴药业集团股份有限公司 | 伊布替尼的药物组合物及其应用 |
| US10993967B2 (en) | 2018-10-17 | 2021-05-04 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| DK3908281T3 (da) | 2019-01-09 | 2024-10-21 | Celgene Corp | Antiproliferative forbindelser og sekundære aktive midler til anvendelse til behandling af multipelt myelom |
| CA3129623A1 (en) | 2019-02-22 | 2020-08-27 | Janssen Pharmaceutica Nv | Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate |
| EP3953345B1 (en) | 2019-04-11 | 2023-04-05 | Janssen Pharmaceutica NV | Pyridine rings containing derivatives as malt1 inhibitors |
| EP3871665A1 (en) | 2020-02-28 | 2021-09-01 | Martin-Luther-Universität Halle-Wittenberg | Inhibitors of rna-binding proteins as anti-cancer drugs |
| WO2021176098A1 (en) * | 2020-03-05 | 2021-09-10 | Université de Lausanne | Modulators of aralar for treating neurological disorders |
| KR20230038521A (ko) * | 2020-07-09 | 2023-03-20 | 얀센 파마슈티카 엔.브이. | 장기 작용 제형 |
| AU2021328320A1 (en) * | 2020-08-21 | 2023-05-04 | Janssen Pharmaceutica Nv | Amorphous form of a malt1 inhibitor and formulations thereof |
| EP3967307A1 (en) * | 2020-09-15 | 2022-03-16 | Instytut Hematologii I Transfuzologii | Use of pim kinase inhibitors to augment the efficacy of anti-cd20 antibody-based therapies in hematologic malignancies and non-malignant conditions |
| CN114469949A (zh) * | 2020-10-27 | 2022-05-13 | 正大天晴药业集团股份有限公司 | 用于治疗弥漫大b细胞淋巴瘤的喹啉衍生物 |
| WO2022184716A1 (en) * | 2021-03-03 | 2022-09-09 | Janssen Pharmaceutica Nv | Combination therapy using a malt1 inhibitor and a btk inhibitor |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| US11807689B1 (en) | 2022-06-01 | 2023-11-07 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11884740B1 (en) | 2022-06-01 | 2024-01-30 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11965032B1 (en) | 2022-06-01 | 2024-04-23 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11814439B1 (en) | 2022-06-01 | 2023-11-14 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| WO2025002340A1 (zh) * | 2023-06-29 | 2025-01-02 | 上海翰森生物医药科技有限公司 | 三并环类抑制剂与抗癌剂在制备抗肿瘤药物中的联合应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6113898A (en) * | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| US7832117B2 (en) * | 2006-07-17 | 2010-11-16 | Nike, Inc. | Article of footwear including full length composite plate |
| CA2663116C (en) | 2006-09-22 | 2014-06-10 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| US8741849B2 (en) | 2007-01-10 | 2014-06-03 | Purdue Research Foundation | Kinase inhibitors and uses thereof |
| MX342405B (es) | 2010-06-03 | 2016-09-28 | Pharmacyclics Inc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| KR20230109775A (ko) * | 2011-10-19 | 2023-07-20 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 인산화효소(btk)의 억제제의 용도 |
| TWI662964B (zh) * | 2012-06-04 | 2019-06-21 | 美商製藥有限責任公司 | 布魯頓氏酪胺酸激酶抑制劑之結晶形式 |
| SG10201805807PA (en) * | 2012-06-26 | 2018-08-30 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
-
2015
- 2015-08-06 AU AU2015300966A patent/AU2015300966A1/en not_active Abandoned
- 2015-08-06 CA CA2956550A patent/CA2956550A1/en not_active Abandoned
- 2015-08-06 CN CN201580047327.7A patent/CN106714909A/zh active Pending
- 2015-08-06 BR BR112017002232A patent/BR112017002232A2/pt not_active Application Discontinuation
- 2015-08-06 WO PCT/US2015/044095 patent/WO2016022853A1/en not_active Ceased
- 2015-08-06 MX MX2017001656A patent/MX2017001656A/es unknown
- 2015-08-06 EP EP15829601.2A patent/EP3177366A4/en not_active Withdrawn
- 2015-08-06 US US14/820,434 patent/US9730938B2/en active Active
- 2015-08-06 JP JP2017505609A patent/JP2017523207A/ja active Pending
- 2015-08-07 TW TW104125847A patent/TWI586354B/zh not_active IP Right Cessation
-
2017
- 2017-07-21 US US15/656,394 patent/US20180071295A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017523207A5 (enExample) | ||
| Gutteridge et al. | Plk1 inhibitors in cancer therapy: from laboratory to clinics | |
| JP2018503610A5 (enExample) | ||
| JP2022180461A5 (enExample) | ||
| JP2012521435A5 (enExample) | ||
| ECSP11011403A (es) | Derivado de benzodiazepina para el tratamiento de neoplasma hematopoyetico y leucemia | |
| CO6640268A2 (es) | Formas de decodificación oral de bendamustina y su uso terapéutico | |
| JP2014198741A (ja) | Ｄｎａ損傷因子増強のためのチェックポイントキナーゼ１阻害剤 | |
| JP2017506624A5 (enExample) | ||
| JP2012510484A5 (enExample) | ||
| CO6382135A2 (es) | Terapia especifica y medicamento que usan ligando de integrina para tratar cancer | |
| JP2013518124A5 (enExample) | ||
| PE20210121A1 (es) | Regimenes de dosificacion superior de g1t38 | |
| JP2018535996A5 (enExample) | ||
| MX2022005596A (es) | Regimen de dosificacion para agentes anti-dll3. | |
| CO2022008437A2 (es) | Métodos de tratamiento del cáncer de pulmón de cé-lulas pequeñas con formulaciones de lurbinectedina | |
| JP2018522028A5 (enExample) | ||
| JP2019526559A5 (enExample) | ||
| JP2017537927A5 (enExample) | ||
| AR081835A1 (es) | Formas de dosificacion oral de bendamustina | |
| JP2018506533A5 (enExample) | ||
| JP2013540734A5 (enExample) | ||
| CR20190203A (es) | Composición farmacéutica con antagonista del receptor de mineralocorticoides y su uso | |
| AR075866A1 (es) | Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica. | |
| Alhowail et al. | Co-administration of imipramine and doxorubicin reduces the survival rate and body weight of mice |